Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigious | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
Bank, bioequivalence, chemistry, commencing, Concentration, conclusion, congenital, consecutive, context, costly, daily, decline, depletion, earliest, Fargo, floating, footnote, forecasted, healthy, hypogonadism, hypogonadotropic, instance, integral, JATENZO, led, LIBOR, Lipocine, listed, LPCN, moderate, narrative, oral, partially, perspective, PK, prevent, quality, ratio, reader, repay, reveal, revolving, secondary, stable, swingline, tentative, tested, TLANDO, tooling, tridecanoate, undecanoate, unfavorable, wholly, XR
Filing tables
Filing exhibits
Related press release
Associated ATRS transcripts
ATRS similar filings
Filing view
External links
Exhibit 32.1
ANTARES PHARMA, INC.
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. 1350)
The undersigned, Robert F. Apple, the Chief Executive Officer of Antares Pharma, Inc. (the “Company”), has executed this Certification in connection with the filing with the Securities and Exchange Commission of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2021 (the “Report”).
The undersigned hereby certifies that:
1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Date: | November 4, 2021 | /s/ Robert F. Apple | |||||||||
| Robert F. Apple | |||||||||||
| President and Chief Executive Officer | |||||||||||